Detalhe da pesquisa
1.
RAS mutations in cutaneous squamous-cell carcinomas in patients treated with BRAF inhibitors.
N Engl J Med
; 366(3): 207-15, 2012 Jan 19.
Artigo
em Inglês
| MEDLINE | ID: mdl-22256804
2.
Inhibition of colony stimulating factor-1 receptor improves antitumor efficacy of BRAF inhibition.
BMC Cancer
; 15: 356, 2015 May 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-25939769
3.
Kinetic phases of distribution and tumor targeting by T cell receptor engineered lymphocytes inducing robust antitumor responses.
Proc Natl Acad Sci U S A
; 107(32): 14286-91, 2010 Aug 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-20624956
4.
Antitumor effects of the investigational selective MEK inhibitor TAK733 against cutaneous and uveal melanoma cell lines.
Mol Cancer
; 11: 22, 2012 Apr 19.
Artigo
em Inglês
| MEDLINE | ID: mdl-22515704
5.
Differential sensitivity of melanoma cell lines with BRAFV600E mutation to the specific Raf inhibitor PLX4032.
J Transl Med
; 8: 39, 2010 Apr 20.
Artigo
em Inglês
| MEDLINE | ID: mdl-20406486
6.
Immunosensitization with a Bcl-2 small molecule inhibitor.
Cancer Immunol Immunother
; 58(5): 699-708, 2009 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-18807035
7.
Host immunity contributes to the anti-melanoma activity of BRAF inhibitors.
J Clin Invest
; 133(24)2023 Dec 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-38099495
8.
Combined treatment with dabrafenib and trametinib with immune-stimulating antibodies for BRAF mutant melanoma.
Oncoimmunology
; 5(7): e1052212, 2016 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-27622011
9.
An Effective Immuno-PET Imaging Method to Monitor CD8-Dependent Responses to Immunotherapy.
Cancer Res
; 76(1): 73-82, 2016 Jan 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-26573799
10.
Improved antitumor activity of immunotherapy with BRAF and MEK inhibitors in BRAF(V600E) melanoma.
Sci Transl Med
; 7(279): 279ra41, 2015 Mar 18.
Artigo
em Inglês
| MEDLINE | ID: mdl-25787767
11.
Inhibition of CSF-1 receptor improves the antitumor efficacy of adoptive cell transfer immunotherapy.
Cancer Res
; 74(1): 153-161, 2014 Jan 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-24247719
12.
Distinct immunological mechanisms of CTLA-4 and PD-1 blockade revealed by analyzing TCR usage in blood lymphocytes.
Oncoimmunology
; 3: e29244, 2014.
Artigo
em Inglês
| MEDLINE | ID: mdl-25083336
13.
CTLA4 blockade broadens the peripheral T-cell receptor repertoire.
Clin Cancer Res
; 20(9): 2424-32, 2014 May 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-24583799
14.
CSF1R signaling blockade stanches tumor-infiltrating myeloid cells and improves the efficacy of radiotherapy in prostate cancer.
Cancer Res
; 73(9): 2782-94, 2013 May 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-23418320
15.
Host immunity contributes to the anti-melanoma activity of BRAF inhibitors.
J Clin Invest
; 123(3): 1371-81, 2013 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-23454771
16.
BRAF inhibitor vemurafenib improves the antitumor activity of adoptive cell immunotherapy.
Cancer Res
; 72(16): 3928-37, 2012 Aug 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-22693252
17.
Host immunity contributes to the anti-melanoma activity of BRAF inhibitors.
J Clin Invest
; 126(1): 402-3, 2016 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-26595810
18.
CTLA4 blockade induces frequent tumor infiltration by activated lymphocytes regardless of clinical responses in humans.
Clin Cancer Res
; 17(12): 4101-9, 2011 Jun 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-21558401
19.
Enhanced antitumor activity induced by adoptive T-cell transfer and adjunctive use of the histone deacetylase inhibitor LAQ824.
Cancer Res
; 69(22): 8693-9, 2009 Nov 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-19861533